Statera Biopharma Inc

Company Profile

Statera Biopharma Inc had its IPO on 2006-07-25 under the ticker symbol STAB.

The company operates in the Healthcare sector and Biotechnology industry. Statera Biopharma Inc has a staff strength of 46 employees.

Stock update

Shares of Statera Biopharma Inc opened at $0 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0 - $0, and closed at $0.

This is a 0% increase from the previous day's closing price.

A total volume of 2,517 shares were traded at the close of the day’s session.

In the last one week, shares of Statera Biopharma Inc have increased by 0%.

Statera Biopharma Inc's Key Ratios

Statera Biopharma Inc has a market cap of $21425, indicating a price to book ratio of 0.1575 and a price to sales ratio of 1.6113.

In the last 12-months Statera Biopharma Inc’s revenue was $3.69 million with a gross profit of $998722 and an EBITDA of $-20583648. The EBITDA ratio measures Statera Biopharma Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Statera Biopharma Inc’s operating margin was -573.26% while its return on assets stood at -23.85% with a return of equity of -286.94%.

In Q3, Statera Biopharma Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 183.5%.

Statera Biopharma Inc’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-2.36 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Statera Biopharma Inc’s profitability.

Statera Biopharma Inc stock is trading at a EV to sales ratio of 314.416 and a EV to EBITDA ratio of -0.6943. Its price to sales ratio in the trailing 12-months stood at 1.6113.

Statera Biopharma Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$21.17 million

Total Liabilities

$11.25 million

Operating Cash Flow

$0

Capital Expenditure

$96913

Dividend Payout Ratio

0%

Statera Biopharma Inc ended 2024 with $21.17 million in total assets and $0 in total liabilities. Its intangible assets were valued at $21.17 million while shareholder equity stood at $-1568038.00.

Statera Biopharma Inc ended 2024 with $0 in deferred long-term liabilities, $11.25 million in other current liabilities, 177421.00 in common stock, $-129482141.00 in retained earnings and $9.27 million in goodwill. Its cash balance stood at $1.84 million and cash and short-term investments were $1.98 million. The company’s total short-term debt was $4,829,998 while long-term debt stood at $0.

Statera Biopharma Inc’s total current assets stands at $4.16 million while long-term investments were $0 and short-term investments were $134603.00. Its net receivables were $348755.00 compared to accounts payable of $3.96 million and inventory worth $1.81 million.

In 2024, Statera Biopharma Inc's operating cash flow was $0 while its capital expenditure stood at $96913.

Comparatively, Statera Biopharma Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$0

52-Week High

$0.3047

52-Week Low

$0.0003

Analyst Target Price

$

Statera Biopharma Inc stock is currently trading at $0 per share. It touched a 52-week high of $0.3047 and a 52-week low of $0.3047. Analysts tracking the stock have a 12-month average target price of $.

Its 50-day moving average was $0.01 and 200-day moving average was $0.04 The short ratio stood at 0.39 indicating a short percent outstanding of 0%.

Around 1219% of the company’s stock are held by insiders while 33.9% are held by institutions.